TY - JOUR
T1 - Efficacy and safety of bronchial thermoplasty in clinical practice
T2 - A prospective, longitudinal, cohort study using evidence from the UK Severe Asthma Registry
AU - Burn, Julie
AU - Sims, Andrew J.
AU - Patrick, Hannah
AU - Heaney, Liam G.
AU - Niven, Robert M.
PY - 2019
Y1 - 2019
N2 - Objectives Use data from the UK Severe Asthma Registry (UKSAR) to assess the efficacy and safety of bronchial thermoplasty (BT) in routine UK clinical practice and to identify characteristics of ' responders'. Design Prospective, longitudinal, cohort, multicentre registry study. Setting All (11) UK centres performing BT. Participants and intervention Patients receiving BT in the UK between 01/06/2011 and 30/09/2016 who had consented to data entry into UKSAR (n=133). Efficacy data were available for 86 patients with a BT baseline and at least one follow-up record. Safety data were available for 131 patients with at least one BT procedure record. Primary and secondary outcome measures Efficacy: AQLQ, ACQ, EuroQol, HADS anxiety and HADS depression scores, FEV 1 (% predicted), rescue steroid courses, unscheduled healthcare visits (A&E/Asthma clinic/GP), hospital admissions and days lost from work/school. Safety: peri-procedural events, device problems and any other safety-related findings. Responder analysis: differences in baseline characteristics of ' responders' (≥0.5 increase in AQLQ at 12 months) and ' non-responders'. Results Following Bonferroni correction for paired comparisons, mean improvement in AQLQ at 12 months follow-up compared with BT baseline was statistically and clinically significant (0.75, n=28, p=0.0003). Median reduction in hospital admissions/year after 24 months follow-up was also significant (-1.0, n=26, p<0.0001). No deterioration in FEV 1 was observed. From 28 patients with AQLQ data at BTBL and 12-month follow-up, there was some evidence that lower age may predict AQLQ improvement. 18.9% (70/370) of procedures and 44.5% (57/128) of patients were affected by an adverse event; only a minority were considered serious. Conclusions Improvement in AQLQ is consistent with similar findings from clinical trials. Other efficacy outcomes demonstrated improving trends without reaching statistical significance. Missing follow-up data impacted this study but multiple imputation confirmed observed AQLQ improvement. The safety review suggested BT is being performed safely in the UK.
AB - Objectives Use data from the UK Severe Asthma Registry (UKSAR) to assess the efficacy and safety of bronchial thermoplasty (BT) in routine UK clinical practice and to identify characteristics of ' responders'. Design Prospective, longitudinal, cohort, multicentre registry study. Setting All (11) UK centres performing BT. Participants and intervention Patients receiving BT in the UK between 01/06/2011 and 30/09/2016 who had consented to data entry into UKSAR (n=133). Efficacy data were available for 86 patients with a BT baseline and at least one follow-up record. Safety data were available for 131 patients with at least one BT procedure record. Primary and secondary outcome measures Efficacy: AQLQ, ACQ, EuroQol, HADS anxiety and HADS depression scores, FEV 1 (% predicted), rescue steroid courses, unscheduled healthcare visits (A&E/Asthma clinic/GP), hospital admissions and days lost from work/school. Safety: peri-procedural events, device problems and any other safety-related findings. Responder analysis: differences in baseline characteristics of ' responders' (≥0.5 increase in AQLQ at 12 months) and ' non-responders'. Results Following Bonferroni correction for paired comparisons, mean improvement in AQLQ at 12 months follow-up compared with BT baseline was statistically and clinically significant (0.75, n=28, p=0.0003). Median reduction in hospital admissions/year after 24 months follow-up was also significant (-1.0, n=26, p<0.0001). No deterioration in FEV 1 was observed. From 28 patients with AQLQ data at BTBL and 12-month follow-up, there was some evidence that lower age may predict AQLQ improvement. 18.9% (70/370) of procedures and 44.5% (57/128) of patients were affected by an adverse event; only a minority were considered serious. Conclusions Improvement in AQLQ is consistent with similar findings from clinical trials. Other efficacy outcomes demonstrated improving trends without reaching statistical significance. Missing follow-up data impacted this study but multiple imputation confirmed observed AQLQ improvement. The safety review suggested BT is being performed safely in the UK.
KW - asthma
KW - bronchoscopy
KW - respiratory physiology
UR - http://www.scopus.com/inward/record.url?scp=85067838247&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2018-026742
DO - 10.1136/bmjopen-2018-026742
M3 - Article
C2 - 31221880
AN - SCOPUS:85067838247
SN - 2044-6055
VL - 9
JO - BMJ Open
JF - BMJ Open
IS - 6
M1 - e026742
ER -